Lisata Therapeutics Inc (LSTA) - News Archive

In the ever-evolving landscape of medical research, the pursuit of effective cancer treatments continues to be a beacon of hope for millions. The recent announcement from Lisata Therapeutics Inc. (NASDAQ: LSTA) and WARP...

In a bold move to redefine the pharmaceutical industry s drug development approach, Lisata Therapeutics Inc. and GATC Health have consummated the initial phase of a strategic collaboration aimed at mitigating risks and...

Certepetide: Advancing Treatment Potential in Pancreatic, Colon, and Appendiceal Cancers Lisata Therapeutics Announces Completion of Enrollment in CENDIFOX Trial Lisata Therapeutics, an emerging biotechnology company de...

Lisata Therapeutics has taken a significant step forward in the fight against cholangiocarcinoma with the recent announcement that the first patient has been treated in the second-line cholangiocarcinoma cohort of the o...

Lisata Therapeutics: Pioneering Innovative Cancer Therapies with Promising Developments in Cholangiocarcinoma and Pancreatic Cancer Treatments In the ever-evolving landscape of oncology, Lisata Therapeutics, Inc. (Nasda...

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, is making significant progress in its clinical trials targeting advanced solid tumors and other serious diseases. The company recently a...

:Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive and lethal liver cancer with limited treatment options. Recent advancements have shed light on Certepetide, a novel therapeutic agent, showing promising effe...

Lisata Therapeutics: Promising Progress in Pancreatic Cancer Treatment Amidst Financial ChallengesLisata Therapeutics, a renowned biopharmaceutical company, has recently announced a major milestone in its journey toward...

Lisata Therapeutics, a leading pharmaceutical company, has reached significant regulatory achievements pertaining to their innovative drug candidates, certepetide for pancreatic cancer and LSTA1 for osteosarcoma. The Eu...

The industry of cancer therapeutics is witnessing a significant milestone with Lisata Therapeutics and Qilu Pharmaceutical announcing the first patient treatment in China under Qilu s Phase 2 trial of an up-and-coming d...

BASKING RIDGE, N.J., April 09, 2024 - Lisata Therapeutics, Inc. (Nasdaq: LSTA), a prominent clinical-stage pharmaceutical company dedicated to pioneering innovative therapies for advanced solid tumors and other severe a...

Lisata Therapeutics, a clinical-stage pharmaceutical company focused on developing groundbreaking therapies for advanced solid tumors and other critical diseases, is gearing up to make its presence felt in the industry...

In the domain of glioblastoma multiforme (GBM) research, Lisata Therapeutics triumphantly announced on January 17, 2024, the beginning of the next significant chapter in its cutting-edge story administering treatment of...

The geme of Oncology has been revolutionized with a plethora of cutting-edge therapeutics, yet the grim burden of gastroesophageal adenocarcinoma stands resilient. Oncology demands continuous innovation, and Lisata Ther...